A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING SINGLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 529, A NOVEL ANTI-ASGR1 MONOCLONAL ANTIBODY, IN HEALTHY SUBJECTS

Authors
Category Primary study
JournalJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: 8a0f6c697491b841485556bc97bae44de58e7006
First added on: Feb 10, 2025